Prima BioMed Ltd is a biotechnology company working primarily in the field of cancer immunotherapy. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 Prima acquired the privately held French immunotherapy company Immutep SA and as a result is now focused on products that work through the LAG3 immune control mechanism. Prima currently has three main products in its pipeline, all acquired with Immutep: IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.

Property Value
dbo:abstract
  • Prima BioMed Ltd is a biotechnology company working primarily in the field of cancer immunotherapy. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 Prima acquired the privately held French immunotherapy company Immutep SA and as a result is now focused on products that work through the LAG3 immune control mechanism. Prima currently has three main products in its pipeline, all acquired with Immutep: IMP321, which is recombinant soluble LAG3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer. IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG3+ activated T cells. This antibody has been licensed to GlaxoSmithKline. IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis (en)
dbo:foundingYear
  • 2001-01-01 (xsd:date)
dbo:industry
dbo:keyPerson
dbo:location
dbo:product
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 46505228 (xsd:integer)
dbo:wikiPageRevisionID
  • 744685931 (xsd:integer)
dct:subject
http://purl.org/linguistics/gold/hypernym
rdf:type
rdfs:comment
  • Prima BioMed Ltd is a biotechnology company working primarily in the field of cancer immunotherapy. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 Prima acquired the privately held French immunotherapy company Immutep SA and as a result is now focused on products that work through the LAG3 immune control mechanism. Prima currently has three main products in its pipeline, all acquired with Immutep: IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG3+ activated T cells. This antibody has been licensed to GlaxoSmithKline. (en)
rdfs:label
  • Prima BioMed (en)
owl:sameAs
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Prima BioMed Ltd (en)
is dbo:wikiPageDisambiguates of
is dbo:wikiPageRedirects of
is foaf:primaryTopic of